Friday, December 10, 2021, Atlanta, GA, 11:30 AM – 1:30 PM Eastern Time

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma (Part 2 of a 4-Part Series)

A Friday Satellite Symposium and Virtual Event Preceding the 63rd ASH Annual Meeting

Location
Omni Atlanta Hotel at CNN Center
190 Marietta St NW
Atlanta, GA 30303
Hotel Phone: (404) 659-0000

Program Schedule — Eastern Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting

Meeting Room
International Ballroom (E-F) - North Tower (M2 Floor)


This event will be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Atlanta, GA preregistration is required as seating is limited.  
 
Faculty
Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Martin Dreyling, MD, PhD
Professor of Medicine III
LMU University Hospital Munich
Dept of Medicine III
Munich, Germany

Loretta J Nastoupil, MD
Associate Professor
Section Chief, Indolent Lymphoma
Section Chief, New Drug Development
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Gilles Salles, MD, PhD
Service Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Moderator:
Ann S LaCasce, MD, MMSc
Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
Associate Professor of Medicine, Harvard Medical School
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts


This activity is supported by educational grants from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, Lilly and Seagen Inc.
Program Schedule — Eastern Time
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting

MODULE 1: Diffuse Large B-Cell Lymphoma

MODULE 2: Follicular Lymphoma

MODULE 3: Mantle Cell Lymphoma

MODULE 4: Current and Potential Future Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma

MODULE 5: Hodgkin Lymphoma

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hodgkin and non-hodgkin lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those therapies in clinical practice.
  • Consider patient age, performance status and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for patients with R/R DLBCL, MCL and FL, and counsel appropriately selected individuals regarding the potential benefits of this therapeutic strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for FL, DLBCL, MCL and HL to support quality of life and continuation of treatment.
  • Recall new data with investigational agents and strategies demonstrating promising activity in various lymphoma subtypes, and discuss clinical trial opportunities with eligible patients.

CE Credit
A CME and ABIM MOC credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr AbramsonConsulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MorphoSys, Mustang Bio, Novartis, Ono Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc. Prof DreylingResearch Support (to Institution): AbbVie Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc; Scientific Advisory Board: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Genmab, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, MorphoSys, Novartis, Roche Laboratories Inc; Speaker Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Novartis, Roche Laboratories Inc. Dr NastoupilAdvisory Committee: ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma, Genentech, a member of the Roche Group, Takeda Pharmaceuticals USA Inc. Dr SallesAdvisory Committee: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Debiopharm, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, MorphoSys, Novartis, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, VelosBioInc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Debiopharm, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, MorphoSys, Novartis, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, VelosBioInc.

MODERATORAnn S LaCasce, MD, MMSc – No relevant conflicts of interest to disclose.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, Lilly and Seagen Inc.

Omni Atlanta Hotel at CNN Center
190 Marietta St NW
Atlanta, GA 30303
Hotel Phone: (404) 659-0000

Meeting Room
International Ballroom (E-F) - North Tower (M2 Floor)

Directions
The Omni Atlanta Hotel at CNN Center is conveniently located within walking distance of the Georgia World Congress Center, where the ASH Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hodgkin and non-hodgkin lymphoma.

There is no fee to participate in this program or live webcast of this event.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live broadcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.